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Abstract
A previous study from our laboratory suggested that prostate cancer metastasis to bone may be mediated, in part, by
preferential adhesion to human bone marrow endothelial (HBME) cells. Tumor cell adhesion to endothelial cells may be
modulated by the effect of cytokines on cell adhesion molecules (CAMs). Tumor necrosis factor-alpha (TNF-α) regulates
VCAM expression on the endothelium and this effect is enhanced by dihydrotestosterone (DHT). Transforming growth
factor-beta (TGF-β) stimulates the expression of α2β1integrin on PC-3 cells. The current study investigated the effects of
the above cytokines and DHT (singularly and in various combinations) upon HBME and prostate cancer cell expression of
VCAM, α2 integrin subunit, and β1 integrin subunit by flow cytometry. We also monitored the effects of the above treatments
on PC-3 cell adhesion to HBME monolayers. The data demonstrate that none of the treatments significantly altered the
expression of selected CAMs on HBME cell and neoplastic prostate cell lines. The treatment of HBME monolayers with
various combinations of cytokines and DHT prior to performing adhesion assays with PC-3 demonstrates that treatments
containing TGF-β reduced PC-3 cell adhesion to HBME monolayers by 32% or greater (P < 0.05). The reduction in
PC-3 cell adhesion to TGF-β-treated HBME monolayers was dose dependent. Interestingly, LNCaP cells but not PC-3
cells treated with TGF-β had a reduced ability to adhere to untreated HBME monolayers. These results suggest that TGF-β
may reduce tumor cell adhesion to bone marrow microvascular endothelium, in vivo. The biological significance of this
observation is discussed.
Introduction
During cancer cell metastasis, tumor cells detach from the
primary mass, enter blood circulation, adhere to vascular
endothelial cells at a specific site, exit blood circulation at
that site, induce angiogenesis, and establish a secondary
mass [1]. Prostate cancer preferentially metastasizes to bone
and causes significant bone pain [2]. A previous study sug-
gested that prostate cancer metastasis to bone may be, in
part, a result of preferential adhesion to human bone marrow
endothelial (HBME) cells [3]. The cell adhesion molecules
(CAMs) responsible for PC-3 cells’ (a prostate cancer cell
line derived from a bone metastasis) interaction with HBME
cells, however, were not extensively examined in that study.
CAMs mediate, in part, the adhesion of tumor cells to the
endothelium. The CAMs on endothelial cells are typically
influenced by inflammatory cytokines such as tumor necro-
sis factor-alpha (TNF-α) [4, 5]. Endothelial cells stimulated
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with TNF-α express increased amounts of vascular cell ad-
hesion molecule-1 (VCAM-1) and E-selectins. Both CAMs
have been shown to mediate tumor cell adhesion to vascu-
lar endothelial cells [5–7]. Interestingly, the TNF-α-induced
expression of VCAM-1 on human umbilical vein endothelial
cells (HUVECs) is enhanced by treatment of HUVECs with
dihydrotestosterone (DHT) [8].
The expression of CAMs on prostate cancer cells is also
regulated by cytokines [9]. The integrin α2β1 mediates PC-
3 cell adhesion to collagen I, which is a major component
of the bone matrix. Furthermore, the expression of this in-
tegrin on PC-3 cells is upregulated by transforming growth
factor-beta (TGF-β), which is a prevalent cytokine in the
bone marrow. TGF-β first binds TGF-β receptor type II,
which presents the TGF-β ligand to TGF-β receptor type I.
The TGF-β receptor type I is activated by phosphorylation
and interacts with an adaptor protein SARA (Smad anchor
for receptor activation). SARA then propagates the TGF-β
signal to intracellular signaling mediators known as Smad2
and Smad3. Smad 2 and 3 interact with Smad 4 and the
Smad complexes are translocated to the nucleus, where they
activate specific genes. Interestingly, Smad 3 is an important
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coregulator for androgen-signaling in prostate cancer cells
[10].
Nakashima et al. [11] reported that serum levels of
TNF-α are elevated in prostate cancer patients. TNF-α fa-
cilitates metastasis by enhancing endothelial cell expression
of CAMs that would in turn mediate cancer cell adhesion
to the endothelium [7]. In addition, the normal physiological
levels of DHT (4–40 nmol/l) can enhance surface expression
of VCAM on TNF-α stimulated endothelial cells [8]. TGF-
β is a prevalent cytokine in the bone matrix and has been
demonstrated to enhance the expression of the collagen I
receptor, α2β1 [12]. It is therefore conceivable that TGF-
β regulates CAM expression on both prostate cancer cells
and HBME cells that can affect their interaction.
Based upon these findings, we examined the interplay
between CAMs, cytokines and androgens such as DHT.
Specifically, the present study investigated the effects that
TGF-β, TNF-α, and DHT (singularly and in various com-
binations) have upon selected prostate cancer cell adhesion
to HBME cell monolayers. We also determined the effect
these soluble factors have on HBME cell expression of
three CAMs: α2 integrin subunit, β1 integrin subunit, and
VCAM. Lastly, we investigated the effects of these soluble
factors on the surface expression of α2 integrin and β1 in-
tegrin subunits on normal and neoplastic prostate cell lines.
TNF-α was excluded from the treatment protocol for normal
and neoplastic prostate epithelial cell lines because it has a
cytotoxic effect on some cancer cell lines in this study [13].
Materials and methods
Cell lines
Human bone marrow endothelial (HBME) cells were devel-
oped and described in a previous publication [3]. Normal
prostate epithelial cells, 267B1, were a generous gift from
Dr Jill Mascoska, University of Michigan Comprehensive
Cancer Center (Ann Arbor, Michigan). WiDr (colon can-
cer cell line), LNCaP (prostate cancer cell line derived
from a lymph node metastasis that expresses androgren re-
ceptor) and PC-3 (prostate cancer cell line derived from a
bone metastasis that does not express androgren receptor)
were obtained from the American Type Culture Collec-
tion (ATCC). HBME and WiDr were maintained in Dul-
becco’s Modified Eagle Medium with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin; LNCaP and
PC-3 were maintained in RPMI Medium with 10% FBS
and 1% penicillin/streptomycin. The immortalized normal
prostate epithelial cell line, 267B1, was maintained in De-
fined Keratinocyte-SFM supplemented with growth factors
(Gibco), 10% FBS and 1% penicillin/streptomycin.
Flow cytometry procedure and analysis
The cell lines were seeded in either T-75 or T-150 flasks and
grown to confluence. Once confluent, the HBME cell mono-
layers, normal and neoplastic epithelial cells were treated as
described in respective figure legends. The concentrations
of DHT and TNF-α were used because they were demon-
strated to increase the expression of VCAM on endothelial
cells [8]. TGF-β concentration was selected because it in-
creased PC-3 adhesion to bone matrix [12]. Before flow
cytometric procedures, one million cells were incubated
with 100 µl of antibodies to α2 integrin subunit, β1 integrin
subunit or VCAM (for HBME cells only) at a concentration
of 10 µg/ml for 45 min at room temperature. The cells were
washed with 10 volumes of PBS, centrifuged and the pellets
were incubated with 10 µg/ml of anti-mouse FITC conjugate
IgG (Sigma Chemical Co., St. Louis, Missouri) for 45 min
at room temperature. Cells incubated with secondary anti-
bodies only served as negative controls. After incubation
with secondary antibodies, cells were washed again with
10 volumes of PBS, fixed with 3% paraformaldehyde, pH
7.4, and analyzed for fluorescence with an Epics Elite Flow
Cytometer (Coulter Corp., Miami, Florida). The percentage
of positive cells was determined by subtracting the negative
control value of the histogram from tested sample values.
The average of two replications is reported.
Adhesion assays
Adhesion assays were performed as reported earlier [3].
Briefly, human bone marrow endothelial (HBME) cells were
seeded onto plastic and grown to confluence in ‘snap-apart’
96-well tissue culture plates (Fisher Scientific, Pittsburgh,
Pennsylvania). Prostate cancer cells (PC-3 or LNCaP) or
HBME cells were treated with various combinations of
cytokines and DHT for approximately 24 h prior to the
adhesion assay. The media containing the treatments were
removed shortly before starting the adhesion assay and
replaced with adhesion media (MEM, 1% bovine serum al-
bumin). Prostate cancer cells were labeled with 51Cr sodium
salt and layered over monolayers of HBME cells for 30 min
at 37 ◦C. The plates were gently washed three times with
PBS and assayed for gamma particle emission using a
gamma counter. Cell adhesion was reported as counts per
minute (CPM) relative to the adhesion of controls, which
were set to 100. Experiments were done in quadruplicates
and repeated a minimum of two times.
Membrane preparation and Western blotting
Cells were dounced in a 20 mM HEPES buffer (pH 7.4) sup-
plemented with 5 mM Na3VO4 and 1 mM phenylmethylsul-
fonylflouride (PMSF). The resulting slurry was centrifuged
at 100 000 × g for 35 min at 4 ◦C to pellet membrane
fractions. The membrane fractions were solubilized in lysis
buffer (20 mM sodium phosphate (pH 7.5), 100 mM NaCL,
1% triton X-100, 0.5% Na+ deoxycholate and 0.1% SDS)
and the protein concentrations were determined. Fifty micro-
grams of protein were resolved on a 7.5% polyacrylamide
ready gel and transferred to a nitrocellulose membrane in
accordance with manufacturer’s instructions (Bio-Rad Lab-
oratories, California). The membrane was blocked overnight
at 4 ◦C with blocking buffer (Tris-buffered saline (TBS)
pH 7.7 {0.05M Tris base, 0.15M NaCL} supplemented with
0.05% tween 20 and 10% nonfat powdered milk), probed for
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1 h at room temperature (RT) with rabbit polyclonal anti-
TGF-β type II receptor (Santa Cruz Biotechnology) diluted
1/5000 in probing solution (TBS pH 7.7 supplemented with
0.1% tween 20 and 2.5% nonfat powdered milk) and washed
four times with probing solution. Next, the membrane was
subjected to goat anti-rabbit IgG secondary antibody di-
luted 1/1000 in probing solution for 1 h at RT, washed four
times and band visualized by chemiluminesence according
to manufacturer’s instructions.
Statistical analysis
For flow cytometry data, equality among treatment effects
were assessed by Kruskal–Wallis tests due to the small num-
ber of replications for each treatment. For adhesion assay
data, natural-log transformed measurements were analyzed
by analysis of variance (ANOVA) to assess treatment effects.
Adjustments for experimental groups were made where ap-
plicable. The estimates represent the expected values of
the experimental group relative to the control group. In the
graphs, the control group is plotted at 100. The estimated
value and its 95% confidence interval were obtained by tak-
ing the anti-logarithm of the results from the analysis of
variance. Statistical analyses were carried out with the SAS
8 software.
Results
The effects of cytokines and DHT on prostate cancer cell
adhesion to HBME monolayers
Adhesion assays were done to determine the effect of solu-
ble factors on HBME cell monolayers’ ability to bind PC-3
cells. The data demonstrates a 39% reduction (95% confi-
dence interval (22%, 52%) in PC-3 cell adhesion to HBME
cells only when the treatment included TGF-β1 (Figure 1,
P = 0.001). Neither TNF-α nor DHT, alone or in combina-
tion, affected PC-3 cell adhesion to HBME cell monolayers.
To determine if the observed decrease in PC-3 cell ad-
hesion to TGF-β-treated HBME cells is dose dependent,
HBME cells were treated with various doses of TGF-β and
then used in adhesion assays. The data demonstrate that
the adhesion of PC-3 cells to TGF-β-treated-HBME cell
monolayers is dose-dependent beyond a concentration of
0.1 ng/ml (Figure 2, P = 0.001).
To determine the effect TGF-β had on PC-3 cells’ and
LNCaP cells’ ability to adhere to HBME monolayers, PC-
3 and LNCaP cells were treated with 10 ng/ml of TGF-β.
This concentration was demonstrated to increase PC-3 cell
adhesion to collagen type I enriched matrix [9]. Our result
demonstrates that treatment of LNCaP cells (P = 0.02), but
not PC-3 cells (P = 0.14), with TGF-β significantly reduces
their ability to adhere to HBME cell monolayers (Table 1).
Western analysis was done on membrane preparations from
cell lines used in this study to evaluate the expression of
TGF-β receptor type II, which binds TGF-β ligand from
the culture fluid [14]. Beta-1 integrin subunit was probed
Table 1. The effect of TGF-β treatment on PC-3 and
LNCaP adhesion to HBME cell monolayers.
Cell lines/treatment Percentage relative to control,
95% confidence interval
LNCaP /Control 100
LNCaP/Treated 56 (36, 87)
PC-3/Control 100
PC-3/Treated 88 (74, 104)
Percent relative to controls of LNCaP and PC-3 cell ad-
hesion to HBME monolayers.
Both LNCaP and PC-3 cells were treated for 24 h with
10 ng/ml of TGF-β prior to being used in adhesion
assays.






HUVEC were probed for the above cell adhesion mole-
cules under non-stimulated and cytokine stimulated
conditions. Maximal expression of E-selectin was de-
tected at 4 h of cytokine stimulation and VCAM max-
imal expression was detected at 16–24 h of cytokine
stimulation. PeCAM does not require cytokine activa-
tion and normally found in high amount on endothelial
cells. The numbers are percentage above background.
Background was determined by the amount of fluores-
cence associated with cells untreated with antibodies.
as control for membrane preparations. The result demon-
strates that TGF-β receptor type II is only expressed in the
WiDr and LNCaP cell lines (Figure 3). As expected, all cell
lines express beta-1 integrin subunit, thus demonstrating the
success of our procedure for isolating membrane-associated
proteins.
The role of DHT in prostate cancer cell adhesion to
HBME was next determined. Unlike PC-3 cells, LNCaP
cells are androgen responsive. The effect of DHT on the
proliferation of LNCaP cell is known [15]. To the authors’
knowledge, however, no information exists regarding the
effect DHT has on LNCaP cells’ ability to adhere to an
endothelial monolayer. Using a broad range of DHT concen-
trations in standard medium supplemented with charcoal-
stripped fetal bovine serum, we demonstrate that DHT does
not reduce LNCaP cell adhesion to HBME monolayers (Fig-
ure 4a). DHT only marginally decreases PC-3 cell adhesion
at the highest dose (200 nmolar), which is above the nor-
mal physiological range [9] (Figure 4b). Because PC-3 cells
do not express androgen receptors, this outcome was not
expected and cannot be explained.
The effects of cytokines and DHT on CAM expression
HBME cells were treated with cytokines and DHT as de-
scribed in Figure 1 for the expression of VCAM-1, α2 and
β1. The concentration of DHT used in this study is within the
normal range of testosterone in human male serum. The data
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Figure 1. PC-3 cell adhesion to HBME cell monolayers treated with cytokines and DHT. The control (solid circle) is the magnitude of PC-3 cell adhesion
to untreated HBME cell monolayer, which is defined as treatment 1. Treatments are as follows: (1) HBME culture media (Control), (2) 500 U/ml of
TNF-α, (3) 10 ng/ml of TGF-β, (4) 500 U/ml of TNF-α and 10 ng/ml of TGF-β, (5) 40 nmol/l of DHT and 500 U/ml of TNF-α, (6) 40 nmol/l of DHT
and 10 ng/ml, (7) 40 nmol/l of DHT, and (8) 40 nmol/L of DHT, 10 ng/ml of TGF-β, and 500 U/ml of TNF-α. The original culture medium was used
as a solvent for each treatment. HBME cells were treated for approximately 24 h. Statistically significant values relative to the control are indicated by
∗(P < 0.05). Bars represent 95% confidence interval based on the ANOVA.
demonstrate no statistically significant difference between
the 8 experimental conditions for surface expression of
VCAM, alpha-2 integrin subunit, and beta-1 intregin subunit
(all P -values are > 0.17) (Figure 5). HUVEC monolayers
were treated as a control for TNF-α effect on endothelial
cells (Table 2). HUVEC are sensitive to TNF-α stimulation
and respond by expressing VCAM and E-selectin. Our data
demonstrate that VCAM and E-selectin expression on HU-
VECs are upregulated by TNF-α treatment, thus indicating
that our TNF-α treatment is effective.
The effect of TGF-β and DHT on α2 and β1 integrin
subunit expression in normal and neoplastic cell lines was
investigated. TNF-α was excluded from treatment regimens
because of its reported cytotoxity on the LNCaP cell line [13,
16]. The data demonstrate that none of the four treatments
significantly affected the expression of α2 and β1 integrin
subunits in any cell line evaluated (all P -values > 0.14)
(Figures 6A and B).
Discussion
The role that important cytokines (i.e., TNF-α and TGF-β)
and androgen may play in prostate cancer cell adhesion to
HBME monolayers has not been studied well. Cytokines
have been demonstrated to regulate the expression of CAMs
on both endothelial cells and prostate cancer cells [12, 17].
The cytokine activation of some endothelial cell types is
enhanced in the presence of DHT [8]. The current study re-
ports the effect of DHT and selected cytokines on endothelial
cells and prostate cancer cells, and gives a rationale for the
cytokines that were evaluated.
Serum levels of TNF-α have been demonstrated to be
elevated in patients with advanced prostate cancer [11].
TNF-α is a potent activator of CAM expression on endothe-
lial cells [17]. CAMs typically expressed on endothelial cell
surfaces in response to TNF-α stimulation are VCAM, E-
selectin and intracellular cell adhesion molecule (ICAM)
[17]. These CAMs are known to mediate adhesion of a
variety of tumor cells to HUVEC [7, 18, 19]. TNF-α in-
duced VCAM expression on HUVEC is enhanced in the
presence of physiologic concentrations of DHT [8]. DHT
alone does not induce VCAM expression. The current study
demonstrates that our immortalized HBME cells do not ex-
press VCAM in response to TNF-α stimulation. This is not
the case for HBME cells immortalized in other laborato-
ries [17, 20]. Interestingly, prostate cancer cell lines used
in this study do not express receptors for VCAM, ICAM
and E-selectin [21, 22]. Galectin-3, which is carbohydrate-
binding protein, is expressed in PC-3 and LNCaP cells and
it has been demonstrated to mediate PC-3 cell adhesion
to HBME monolayers [4, 23]. Although the receptor for
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Figure 2. The effect of ascending concentrations of TGF-β on PC-3 cell adhesion to HBME cell monolayers. The control (solid circle) is the magnitude of
PC-3 cell adhesion to untreated HBME cell monolayers. Statistically significant values relative to the control are indicated by ∗(P < 0.05). Bars represent
95% confidence interval based on the ANOVA.
Figure 3. Western blot analysis of TGF-β receptor type II in membrane preparations of selected human cell lines. Beta-1 integrin subunit was evaluated
as a control for the membrane associated proteins.
galectin-3 has not been identified, the data demonstrate that
TNF-α stimulation does not alter its expression. The data
generated during this investigation, therefore, suggest that
TNF-α stimulation does not mediate prostate cancer cell ad-
hesion to HBME cell monolayers via well-known inducible
endothelial CAMs or unknown CAMs.
Although concentrations of plasma TGF-β do not corre-
late with progression of prostate cancer [23], this cytokine
is prevalent in the bone, the preferred metastatic site for
prostate cancer [24]. Kostenuik et al. [12] demonstrated
that TGF-β upregulated PC-3 expression of α2β1 and sub-
sequently upregulated PC-3 cell adhesion to collagen type I.
Data presented here does not support this phenomenon. Flow
cytomeric analysis demonstrated that TGF-β did not alter
α2β1 expression on PC-3 cells and several cell lines in-
cluding a colon cancer cell line (WiDr), a prostate cancer
cell line derived from a lymph node metastasis (LNCaP), a
normal prostate epithelial cell line immortalized with SV40
(NP,267B-1) [25] and our immortalized HBME cells. The
difference between Kostenuik et al.’s study and the current
study is that cell lysates were probed for α2β1 in the former
study. In the latter study, flow cytometry was used to evaluate
α2β1 expression at the cell surface. The inability of TGF-
β to induce any response in selected cell lines was not due
to the presence or absence of TGF-β receptor type II. We
focused solely on receptor type II because it is responsible
for binding TGF-β ligand from the medium and activating
the signaling pathway [10]. TGF-β type II receptors were
detected in WiDr and LNCaP cell membrane preparations
by Western blotting. A previous study demonstrated that
LNCaP and PC-3 cells expressed TGF-β receptor type II
[15]. A more recent study [26] demonstrated that LNCaP
cells do not express TGF-β receptor type II under con-
ventional cell culture conditions. The objectives of these
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Figure 4. The effect of DHT on prostate cancer cell adhesion to HBME cell monolayers. A. LNCaP cells (A) and PC-3 cells (B) were treated for 24 h
with increasing nanomolar concentrations of DHT dissolved in standard culture medium supplemented with charcoal-stripped fetal bovine serum. The
control (solid circle) is the magnitude of untreated LNCaP cell adhesion to HBME cell monolayers. Statistically significant values relative to the control
are indicated by ∗(P < 0.05).
particular experiments were (1) to determine if TGF-β up-
regulated α2β1 integrin expression in PC-3 cells only and
(2) to determine if α2β1 integrin plays a role in prostate
cancer cell preferential adhesion to HBME in vitro. Alpha-
2, beta-1 integrin mediates cell adhesion to extra-cellular
matrix (ECM) components collagen type I, II, III and IV
[22]. However, it is known that CAMs that mediate cell-to-
ECM interactions can also mediate cell-to-cell interactions
such as α5β1 mediating the adhesion of human osteosarcoma
cells, human melanoma cells and human kidney carcinoma
cells to HUVEC [27]. The ligand for α5β1 integrin is ECM
component fibronectin [22]. Our data demonstrate that α2β1
integrin is equally expressed on LNCaP, normal prostate ep-
ithelial cells and PC-3 cells, and slightly more expressed
on the WiDr cells. WiDr cells adhere poorly to HBME cell
monolayers and are used as a negative control in our adhe-
sion assays [3]. Based on these observations, we conclude
that α2β1 integrin does not mediate preferential adhesion of
prostate cancer cells to HBME cell monolayer.
The current study demonstrates that treatment of HBME
monolayers with TGF-β significantly reduces their ability
to bind PC-3 cells. The TGF-β treatment of LNCaP and not
PC-3 cells also reduces their ability to bind HBME monolay-
ers. This occurred despite our inability to detect TGF-β type
II receptors on HBME cells. The TGF-β mediated inhibition
was first demonstrated in a murine model consisting of P815
mastocytoma and microvascular endothelial cells [28]. The
CAMs regulated by TGF-β were not identified in that study
or the current study. The amount of TGF-β in the bone is
greater than in any other organ [12]. Based on Bereta et al.’
[28] and our observations, its presence in the bone should
reduce the incidence of bone metastasis. This suggests that
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Figure 5. The effect of selected cytokine and DHT treatments on α2β1 and VCAM expression on HBME cells as determined by flow cytometry. Treatments
are as follows: (1) HBME culture media (Control), (2) 500 U/ml of TNF-α, (3) 10 ng/ml of TGF-β, (4) 500 U/ml of TNF-α and 10 ng/ml of TGF-β, (5)
40 nmol/l of DHT and 500 U/ml of TNF-α, (6) 40 nmol/l of DHT and 10 ng/ml, (7) 40 nmol/l of DHT, and (8) 40 nmol/l of DHT, 10 ng/ml of TGF-β, and
500 U/ml of TNF-α. The original culture medium was used as a solvent for each treatment. HBME cells were treated for approximately 24 h, the medium
was removed and replaced with adhesion assay medium.
other factors in the bone may be negating the TGF-β effect
on bone marrow endothelial cells and/or the concentration of
TGF-β in the bone is not sufficient to alter CAM expression
on the endothelium or metastasizing prostate cancer cells.
Our data demonstrate a reduction in PC-3 cell adhesion to
HBME cell monolayers at TGF-β concentrations exceeding
0.1 ng/ml. Using a murine model, Bereta and colleagues
[28] demonstrated a reduction at TGF-β concentrations ex-
ceeding 0.5 ng/ml. Another explanation may be that TGF-β
reduces bone metastasis in cancer cells that are TGF-β
responsive, like LNCaP. The ability of TGF-β to reduce
LNCaP but not PC-3 cell adhesion to HBME monolayers
may explain the inability of LNCaP cells to metastasize to
bone. Because TGF-β reduces HBME monolayers’ ability
to bind PC-3 but enhances PC-3’s ability to bind collagen I,
this cytokine may have mediated PC-3’s ability to detach
from the bone marrow endothelium and attach to the under-
lying bone matrix, which is composed mainly of collagen I
[12].
In summary, this investigation demonstrates that DHT
and TNF-α do not alter prostate cancer cell adhesion to bone
marrow endothelial cells in vitro. Although TNF-α induces
the expression of VCAM and E-selectin on HUVEC, it does
not induce the expression of these CAMs on our established
HBME cell line. HBME cell monolayers treated with TGF-β
have a reduced affinity for prostate cancer cells in vitro. The
TGF-β mediated effect is dose dependent. Because TGF-β
is a common cytokine in the bone microenvironment, which
is a common site for prostate cancer metastasis [12], it is un-
likely that the effect of TGF-β on bone marrow endothelial
cells prevents metastasis. We therefore speculate that TGF-β
may play a role in releasing the attached cancer cells from
the endothelium and upregulating their adhesion to the col-
lagen I enriched bone matrix via enhanced α2β1 expression
[9, 12]. The prevalence of TGF-β in the bone and its ability
to reduce endothelial cell binding to prostate cancer cells
may be exploited to prevent skeletal complications associ-
ated with metastatic prostate cancer. Studies are currently
underway to identify the CAMs on HBME cells that are
regulated by TGF-β.
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